Boehringer Ingelheim Partners with EMFRET Analytics to Develop First-in-Class Antibody Targeting Stroke Induced Brain Inflammation

Boehringer Ingelheim and EMFRET Analytics partner to develop EMA601, a first-in-class stroke therapy that targets GPVI to prevent brain inflammation and clots.

By: AXL Media

Published: Mar 31, 2026, 4:13 AM EDT

Source: Information for this report was sourced from University of Würzburg

A Decades Long Journey from Discovery to Development

The advancement of stroke therapy has reached a pivotal milestone with the formal collaboration between global pharmaceutical leader Boehringer Ingelheim and EMFRET Analytics. At the center of this agreement is EMA601, a therapeutic antibody that traces its origins back 25 years to the research laboratories of the University of Würzburg. Unlike traditional anticoagulants, this compound specifically inhibits the glycoprotein VI (GPVI) receptor found on the surface of blood platelets. This targeted approach allows the drug to neutralize the primary drivers of stroke related damage while leaving the body's essential blood-clotting mechanisms intact, a balance that has long eluded researchers in the field of experimental biomedicine.

Targeting the Receptor of Pathological Clotting

The scientific foundation for EMA601 was established in 2001 when Professor Bernhard Nieswandt first identified the critical role of GPVI in the development of thrombosis. Found exclusively on platelets and their precursor cells, GPVI binds to exposed collagen on damaged vessel walls, triggering the activation that leads to vessel occlusion. While this process is necessary for healing minor injuries, its overactivation during a stroke causes the formation of massive clots that starve the brain of oxygen. By neutralizing this specific receptor, EMA601 prevents the formation of these lethal blockages without significantly disturbing the normal hemostasis required to prevent internal bleeding.

Addressing the Hidden Threat of Thrombo Inflammation

One of the most persistent challenges in modern stroke care is that nearly half of patients do not achieve full recovery even after a successful "recanalization," or the removal of a blood clot. This is often due to a process known as thrombo-inflammation, where the initial vessel occlusion triggers a secondary wave of inflammatory tissue damage in the downstream areas of the brain. Professor Guido Stoll, a pioneer in the study of neuroinflammation, explains that this process remains active even after blood flow is restored, causing the brain infarct to continue growing. EMA601 is designed to be used as an adjunct therapy alongside existing treatments, specifically to halt this inflammatory growth and preserve more brain tissue.